LataMed AI Corp. (OTC: LMED) provided a shareholder update on Monday regarding the implementation of its previously announced 5-for-1 forward stock split and the related mandatory share exchange process. As of July 7, 2026, the company has submitted all required information to FINRA, and management anticipates the corporate action will become effective within approximately the next week, pending FINRA's review and final processing.
The forward stock split will be accompanied by a new CUSIP number, 21116R404, which will replace the current CUSIP upon effectiveness. This change is designed to facilitate the mandatory share exchange process. The company emphasized that shareholders holding shares through brokerage accounts or in book-entry form generally do not need to take any action, as their accounts will be updated automatically. However, physical certificate holders are advised that their existing certificates represent the pre-exchange security and will be processed according to exchange procedures when submitted for transfer, sale, or exchange.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated: "We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. While the vast majority of shareholders are expected to have their shares updated automatically, we believe it is important to provide clear guidance for those holding physical certificates." He added that post-split, management will focus on advancing the company's telemedicine platform and pursuing licensing opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms, which are key to building an integrated digital healthcare ecosystem in Latin America.
The company believes the forward stock split supports its corporate development and strategic initiatives, facilitating the implementation of the new CUSIP and updated capital structure. Additional details on exchange procedures will be provided by the company's transfer agent as the process moves forward. LataMed AI encourages shareholders with questions to contact their brokerage firm or the transfer agent once detailed instructions are available.
For more information, visit https://latamed.ai or review the company's SEC filings at www.sec.gov.
